Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...
Anyone who calls Oak Partners, or fills out a form on the website seeking information on becoming a client, will likely get to have a phone conversation with the firm’s ...